BioFocus Signs an Integrated Drug Discovery Collaboration with Boehringer Ingelheim

Galapagos has announced that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim. 

Under the terms of the agreement, BioFocus will apply its extensive drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio.

David Smith, CEO Galapagos Services, commented: “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading research-based pharmaceutical companies and a new integrated drug discovery client to BioFocus. It is testament to the strength and depth of BioFocus’ drug discovery capabilities and expertise in this particular gene family.”